CAR 002
Alternative Names: CAR-002Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Caravan Biologix
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Carcinoma
Most Recent Events
- 18 Dec 2024 Preclinical trials in Carcinoma in USA (Parenteral) before December 2024 (Caravan Biologix pipeline, December 2024)